- Home
- RXT vs LRMR Comparison
RXT vs LRMR Comparison
Compare RXT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXT | LRMR |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.7M | 332.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RXT | LRMR |
|---|---|---|
| Price | $1.04 | $3.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $1.61 | ★ $16.71 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,688,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $1.61 |
| 52 Week High | $3.03 | $6.91 |
Technical Indicators
Market Signals| Indicator | RXT | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 46.32 |
| Support Level | $1.16 | $3.32 |
| Resistance Level | $1.14 | $3.79 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 18.75 | 58.77 |
Price Performance
Historical ComparisonAbout RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.